China-headquartered Fapon, a global life science company, and Bio Farma, a state-owned pharmaceutical holding company in Indonesia specialising in vaccines, life science products, and other pharmaceuticals, have signed a Memorandum of Understanding (MoU) to formalise their commitment to strengthening medical innovations in Indonesia.

In doing so, the MoU will further solidify Fapon’s global ecosystem for diagnostics and medical treatment. Jielun ZHU, Chief Financial Officer and Chief Investment Officer of Fapon, I.G.N. Suharta Wijaya, Finance and Risk Management Director of Bio Farma and Sri Harsi Teteki, Medical, Institutional and Governance Relations Director of Bio Farma attended the official signing ceremony.

The partnership between Fapon and Bio Farma focuses on developing biological medicines and technologies, medical devices, and IVD solutions with an emphasis on healthcare localisation. The goal is to foster a synergistic collaboration between the two companies, drive medical innovation and technology transfer, and boost the development of healthcare industry in Indonesia.

Sri Harsi Teteki stated that the partnership with Fapon will leverage the strengths of both companies to innovate medical technologies and, ultimately contribute to the enhancement of healthcare services in the country.